Lia DeGroot

Pfiz­er is chal­leng­ing the Covid-19 vac­cine patents that Mod­er­na has ac­cused the com­pa­ny of in­fring­ing be­fore the Patent Tri­al and Ap­peal Board (PT­AB), ar­gu­ing that

The FDA on Fri­day pub­lished fi­nal guid­ance ex­plain­ing how it will not en­force some pro­vi­sions of a ma­jor sup­ply chain law un­til next year, rather

As­traZeneca is the lat­est phar­ma com­pa­ny to chal­lenge the In­fla­tion Re­duc­tion Act in court, this time ze­ro­ing in on the law’s pro­vi­sions around or­phan drugs.

Eli Lil­ly’s Retev­mo to treat ad­vanced or metasta­t­ic re­arranged dur­ing trans­fec­tion (RET)-mu­tant medullary thy­roid can­cer (MTC) showed promis­ing re­sults at im­prov­ing pro­gres­sion-free sur­vival com­pared to

The Biden ad­min­is­tra­tion’s new bio­med­ical re­search agency is launch­ing a $24.8 mil­lion project to de­vel­op mR­NA plat­forms with the goal of us­ing the tech­nol­o­gy to

HHS on Tues­day an­nounced it’s pump­ing $1.4 bil­lion in gov­ern­ment funds in­to next-gen Covid-19 med­ical prod­ucts in the pipeline, in­clud­ing $326 mil­lion to Re­gen­eron to

CMS laid out the first part of its plan to al­low Medicare ben­e­fi­cia­ries to pay for pre­scrip­tion drugs in month­ly in­stall­ments, as di­rect­ed by the

The FDA will con­vene its on­col­o­gy ad­vi­so­ry com­mit­tee in Oc­to­ber to dis­cuss Lumakras, Am­gen’s KRAS-in­hibit­ing oral med­ica­tion as a sec­ond-line treat­ment for KRAS G12C-mu­tat­ed non-small

The AARP on Fri­day filed an am­i­cus brief ask­ing a judge to up­hold the In­fla­tion Re­duc­tion Act, ar­gu­ing that stop­ping the drug price ne­go­ti­a­tion pro­gram

In a rare move, the FDA is­sued a no­tice of non­com­pli­ance to an on­col­o­gy com­pa­ny for fail­ing to sub­mit clin­i­cal da­ta on its treat­ment for